Fig. 3: Adverse events experienced by ≥10% of patients with BRAF/MEK combination therapies.

a Adverse events (AEs) shown for dabrafenib plus trametinib occurred in at least 10% of patients in combined data from interim analysis of treatment-naive and previously treated patients^15,16. AEs led to dose reduction, dose interruption, and permanent treatment discontinuation in 37%, 67%, and 16% of patients. ^aChest pain includes musculoskeletal chest pain. b Treatment-related AEs (TRAEs) shown for encorafenib plus binimetinib occurred in at least 10% of patients¹⁸. TRAEs led to dose reduction, dose interruption, and permanent treatment discontinuation in 24%, 44%, and 15% of patients. Comparisons of safety profiles should be done cautiously since data are from different trials and reported as all-causality AEs for one treatment combination and as TRAEs for the other combination. ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CNS central nervous system, CPK creatine phosphokinase.